A patient with stage IV lung adenocarcinoma undergoing chemoimmunotherapy developed COVID-19 pneumonia. This case report describes the experience with tocilizumab treatment for this patient after the first cycle of chemoimmunotherapy. The patient tested positive for COVID-19 via nasopharyngeal swab and reverse transcriptase polymerase chain reaction testing. The clinical outcome suggests that tocilizumab can be safely used to treat COVID-19 pneumonia in patients undergoing chemoimmunotherapy.
